創傷和急診醫學科
早期貧血處置
Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. (開啟新視窗)
出處: Pharmacotherapy 2008;28(11):1383-90.
檢索: PubMed 18956998
DOI碼: 10.1592/phco.28.11.1383
Recombinant human erythropoietin in severe anaemia: issues of dosing and duration. (開啟新視窗)
出處: Anaesth Intensive Care 2006;34(6):793-6.
檢索: PubMed 17183900
Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia. (開啟新視窗)
出處: N Engl J Med. 2023 2;389(18):1649-59.
檢索: PubMed 37913505
DOI碼: 10.1056/NEJMoa2303706
Bloodless management of the anemic patient in the emergency department. (開啟新視窗)
出處: Ann Emerg Med 2022;79(1):48-57.
檢索: PubMed 34353645
DOI碼: 10.1016/j.annemergmed.2021.06.015
Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. (開啟新視窗)
出處: J Trauma 2008;65(2):285-97.
檢索: PubMed 18695463
DOI碼: 10.1097/TA.0b013e31817f2c6e
Erythropoiesis in multiply injured patients. (開啟新視窗)
出處: J Trauma 2006;61(5):1285-91.
檢索: PubMed 17099548
DOI碼: 10.1097/01.ta.0000240969.13891.9b
Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. (開啟新視窗)
出處: Arch Surg 2012;147(3):251-5.
檢索: PubMed 22430906
DOI碼: 10.1001/archsurg.2011.1838
Zeugen Jehovas und Schwerverletzung mit drohender Hämorrhagie. Wie komplex ist die Behandlung? [Jehovah's Witnesses and severe injury with impending hemorrhaging: how complex is the treatment?] [German, English abstract] (開啟新視窗)
出處: Chirurg 2011;82(6):531-5.
檢索: PubMed 21088815
DOI碼: 10.1007/s00104-010-1999-y